Day: August 16, 2024

NAPLES, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) — via IBN — HealthLynked Corp. (OTCQB: HLYK), a leading provider of healthcare networking and technological innovation, has reported its financial results for the three- and six-month periods ending June 30, 2024. Reflecting the company’s ongoing efforts to streamline operations and transition its revenue streams from legacy clinical operations to app-based services, HealthLynked achieved significant cost reductions, leading to an 8% quarter-over-quarter improvement in its loss from operations. Financial Highlights:Revenue: The company reported revenue of $0.78 million in the second quarter of 2024, a 21% decrease from $1.00 million in the first quarter of 2024, and a 53% decline from $1.70 million in the second quarter of 2023. For the first half of 2024, revenue totaled...

Positive randomized Phase 2 CM24 pancreatic cancer study interim data presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting demonstrates improvement in overall survival, progression free survival, objective response rate and all other efficacy endpoints in the combination of CM24+nivolumab and NAL-IRI/5FU/LV chemotherapy cohort Evaluating expansion of CM24 clinical program to a biomarker driven study in additional indications based on CEACAM1 novel oncology target on Neutrophil Extracellular Traps (NETs) in addition to enhancing immune response through the inhibition of CEACAM1 to CEACAM1 interactions Cash runway extended to Q3 2025 REHOVOT, Israel, Aug. 16, 2024 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class...

Strong Financial Position with ~$220 million cash and cash equivalents Returned Capital to Shareholders via Active Share Repurchase Program Introduced Officially Licensed NFL Team Golf Carts Exclusively Available at Lowe’sJINHUA, China, Aug. 16, 2024 (GLOBE NEWSWIRE) — Kandi Technologies Group, Inc. (the “Company”, “we” or “Kandi”) (NASDAQ GS: KNDI), today announced its financial results for the second quarter of 2024. Second Quarter HighlightsTotal revenues increased to $39.1 million, up from $36.0 million in the same period of 2023. Off-road vehicles and associated parts were the primary driver of revenue, increasing by 11.3% y/y to $34.7 million, compared to $31.3 million in the same period of 2023. Net income was $1.6 million, or $0.02 income per fully diluted share, compared to net income of $4.4 million, or $0.06 income...

– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company to host conference call and webcast today, August 16th at 8:30 AM ET OCALA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the second quarter 2024. As previously announced, the Company will host a conference call and webcast today, Friday, August 16, 2024, at 8:30 AM ET (details below). “We continue to see great potential in Ampligen as we progress across our clinical development programs and look forward to results from our ongoing studies in the near future. Our entire team remains dedicated to patients and stockholders and will continue to drive momentum across our operational, clinical...

Following recent transactions and cost-cutting efforts, Sol-Gel’s cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026 SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoing Sol-Gel sells its rights in the Abbreviated New Drug Application (ANDA)drug product generic to Zoryve® Cream(roflumilast cream 0.3%) Following management realignment, Mr. Mori Arkin, the Company’s executive chairman and controlling shareholder to be appointed as Company’s interim CEO as of January 1, 2025, subject to shareholders approval Sol-Gel recently signed license agreements with respect to TWYNEO and EPSOLAY in...

TULIKIVI CORPORATION  HALF YEAR FINANCIAL REPORT  16 AUG 2024 AT 1 PM – The Tulikivi Group’s net sales were EUR 9.3 million (Q2/2023: EUR 13.3 million) in the second quarter and EUR 17.8 million (H1/2023: EUR 26.4 million) in the review period.– The Tulikivi Group’s operating profit was EUR 0.8 (2.3) million in the second quarter and EUR 1.1 (3.6) million in the review period.– The Tulikivi Group’s profit before taxes was EUR 0.6 (2.2) million in the second quarter and EUR 0.7 (3.3) million in the review period.– The equity ratio at the end of the review period was 49.4 per cent (44.6).– Order books stood at EUR 3.5 (13.9) million at the end of the review period.– The conditions for the implementation of the talc project improved– Future outlook: Net sales in 2024 are expected to be EUR 37 to 44...